Author: Newsdesk

VANCOUVER, BC, Nov. 25, 2020 /CNW/ – Trading resumes in:

Company: Black Mammoth Metals Corporation

TSX-Venture Symbol: BMM

All Issues: Yes

Resumption (ET): 9:30 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

PALO ALTO, Calif., Nov. 25, 2020 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Zokinvy™ (lonafarnib) for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient Progeroid Laminopathies (PL).  

Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8809251-eiger-biopharmaceuticals-fda-approval-zokinvy-progeria/ 

Progeria and Progeroid Laminopathies are separate and distinct ultra-rare, genetic, premature aging diseases that accelerate mortality in young patients.  Disease manifestations include growth failure, loss of body fat and hair, aged-looking skin, stiffness of joints, hip dislocation, generalized atherosclerosis, cardiovascular disease and stroke.  Untreated children with Progeria die of heart disease at an average age of 14.5 years.  There are 20 children and young adults with Progeria and PL identified and followed in the U.S.  

Zokinvy is a disease-modifying agent that has demonstrated a statistically significant survival benefit in children and young adults with Progeria.  In patients with Progeria, Zokinvy reduced the incidence of mortality by 60% (p=0. 0064) and increased average survival time by 2.5 years.  The most commonly reported adverse reactions were gastrointestinal (vomiting, diarrhea, nausea), and most were mild or moderate (Grade 1 or 2) in severity.  Many Progeria patients have received continuous Zokinvy therapy for more than 10 years.

The increase in survival observed with Zokinvy was derived from two open-label clinical trials (N=62) conducted at Boston Children’s Hospital.  The survival analysis compared Zokinvy-treated versus Zokinvy-naïve subjects with Progeria born in or after 1991, by age, gender, and geographic location. Zokinvy-naïve patients originated from a separate natural history study (n=81) conducted by The Progeria Research Foundation.

With this approval, the FDA issued a Rare Pediatric Disease Priority Review Voucher (PRV) to Eiger.  The Rare Pediatric Disease Priority Review Voucher program is designed to encourage development of new drugs and biologics for the prevention or treatment of rare pediatric diseases.  Eiger plans to sell the PRV and under the terms of the Collaboration and Supply Agreement with the Progeria Research Foundation (PRF) will share the proceeds equally with PRF. 

“The FDA approval of Zokinvy is the result of a pioneering partnership between Eiger BioPharmaceuticals and (PRF) to bring the first approved therapy to children, young adults and families living with this devastating disease,” said David Cory, President and CEO of Eiger.  “We are very proud that the first drug approval at Eiger confers a survival benefit to patients with one of the most ultra-rare, and ultimately fatal, pediatric diseases.  We are extremely grateful to all the children, young adults and their families who have made this possible through participation in the Zokinvy clinical trials.”

“The approval of this breakthrough therapy is a critical milestone for the Progeria community and also for Eiger,” said Thomas Dietz, PhD, Chairman of the Board at Eiger.  “The Eiger Board congratulates and commends the management team for their incredible dedication leading the company through its first NDA filing and approval, a major accomplishment for Eiger.”

PRF Medical Director, Leslie Gordon, MD, PhD, added, “Shortly after our son, Sam, was diagnosed with Progeria, my family and I founded The Progeria Research Foundation to find the cause, treatments, and cure for all children with this fatal disease.  This first approved medication is a truly incredible milestone for the Progeria community as we forge ahead toward finding the cure.  We are thrilled to have Eiger as a partner in bringing Zokinvy to the approval finish line, and for their commitment to ensuring patient access to Zokinvy moving forward.”

In support of the patient and healthcare provider community, Eiger is launching our dedicated service center, Eiger OneCare™.  This specialized team will offer personalized support, financial assistance, and access to Zokinvy, all designed for Progeria and processing-deficient Progeroid Laminopathy patients.  Eiger OneCare™ will be available Monday through Friday from 9 AM to 5 PM Eastern Time at 1-833-MYEIGER (1-833-693-4437).

Investor Call
Eiger will host a conference call November 23 at 8:30 AM ET / 5:30 AM PT to discuss the Zokinvy approval.  The live and replayed webcast of the call will be available through the company’s website at www.eigerbio.com.  To participate in the live call by phone, dial (844) 743-2495 (U.S.) or (661) 378-9529 (international) and enter the passcode 5685423.  The replay of the call will be available for one year.

For full prescribing information, visit www.zokinvy.com.

About Zokinvy (lonafarnib)
Zokinvy blocks the accumulation of defective, farnesylated proteins which form tight associations with the nuclear envelope, leading to cellular instability and the process of premature aging in children and young adults with Progeria and processing-deficient Progeroid Laminopathies.

Eiger licensed exclusive worldwide rights to lonafarnib from Merck, known as MSD outside of the United States and Canada.  Merck will not receive any milestone payments for the development of lonafarnib for the treatment of Progeria, and has waived royalty obligations from Eiger for a specified quantity of lonafarnib. 

About
 
Progeria and Progeroid Laminopathies
Progeria, also known as Hutchinson–Gilford Progeria Syndrome (HGPS), and Progeroid Laminopathies are separate and distinct ultra-rare, fatal, genetic premature aging diseases that accelerate mortality in young patients.

Progeria is caused by a point mutation in the LMNA gene, yielding the farnesylated aberrant protein, progerin.  Progeroid Laminopathies are genetic conditions of accelerated aging caused by a constellation of mutations in the LMNA and/or Zmpste24 genes yielding farnesylated proteins that are distinct from progerin.  While nonprogerin producing, these genetic mutations result in disease manifestations with phenotypes that have overlap with, but are distinct from, Progeria.

Without Zokinvy therapy, children with Progeria die of the same heart disease that affects millions of normally aging adults (arteriosclerosis), but at an average age of 14.5 years.  Disease manifestations include severe failure to thrive, scleroderma–like skin, global lipodystrophy, alopecia, joint contractures, skeletal dysplasia, global accelerated atherosclerosis with cardiovascular decline, and debilitating strokes.  It is estimated that there are 400 children worldwide with Progeria and 200 children with Progeroid Laminopathies.  Of these patients, approximately 180 children and young adults have been identified, including 20 in the U.S. and 23 in Europe.

INDICATION

ZOKINVY is indicated in adult and pediatric patients 12 months of age and older with a body surface area (BSA) of 0.39 m² and above:

• To reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS)
• For the treatment of processing-deficient Progeroid Laminopathies with either:
• Heterozygous LMNA mutation with progerin-like protein accumulation
• Homozygous or compound heterozygous ZMPSTE24 mutations

Limitations of Use

ZOKINVY is not indicated for use in patients with non-HGPS Progeroid Syndromes or with Progeroid Laminopathies known to be processing-proficient. Based upon its mechanism of action, ZOKINVY would not be expected to be effective in these populations.

Contraindications

• Strong or moderate CYP3A inhibitors or inducers
• Midazolam
• Lovastatin, simvastatin, and atorvastatin

IMPORTANT SAFETY INFORMATION

• The most common adverse reactions are vomiting (90%), diarrhea (81%), infection (78%), nausea (56%), decreased appetite (53%), fatigue (51%), upper respiratory tract infection (51%), abdominal pain (48%), musculoskeletal pain (48%), electrolyte abnormalities (43%), headache (37%), decreased weight (37%), increased aspartate aminotransferase (35%), myelosuppression (35%), cough (33%), decreased blood bicarbonate (33%), hypertension (29%), and increased alanine aminotransferase (27%).

Gastrointestinal Adverse Reactions

• Gastrointestinal adverse reactions were the most frequently reported adverse reactions. Of the 57 patients (90%) that experienced vomiting, 30 (53%) patients had mild vomiting, 26 (46%) patients had moderate vomiting, and 1 (2%) patient had severe vomiting.
• Of the 35 patients (56%) that experienced nausea, 34 (97%) patients had mild nausea and 1 (3%) patient had moderate nausea.
• Of the 51 patients (81%) that experienced diarrhea, the majority of patients (92%) experienced mild or moderate diarrhea; 38 (75%) patients reported mild diarrhea and 9 (18%) patients reported moderate diarrhea. Four (8%) patients reported severe diarrhea.
• Loss of fluids and dehydration can be severe, leading to hospitalization. As a result, patients should receive therapy for diarrhea at the earliest signs in order to avoid possible severe complications.

Alanine Aminotransferase and Aspartate Aminotransferase Elevations

• Increased alanine aminotransferase was commonly reported (17 [27%] patients). Of the 17 patients with increased alanine aminotransferase, 14 (82%) patients had mild increases, 1 (6%) patient had moderate increases, and 2 (12%) patients had severe increases.
• Increased aspartate aminotransferase was also commonly reported (22 [35%] patients). Of the 22 patients with increased aspartate aminotransferase, 21 (95%) patients had mild increases and 1 (5%) patient had a severe increase.

Hypertension

• Increases in blood pressure have been documented in patients treated with ZOKINVY. At baseline 22 (35%) patients had either a systolic blood pressure or a diastolic blood pressure or both above the 95th percentile. Over the course of the trials, 18 (29%) patients had hypertension based on systolic blood pressure or diastolic blood pressure measurements above the 95th percentile on 3 or more occasions. Five (8%) patients who were normotensive at baseline had either systolic blood pressure or diastolic blood pressure above the 95th percentile at the end of treatment.

Ophthalmic Adverse Reactions

• Lonafarnib caused retinal toxicity in monkeys at 3.7 times the human dose based on plasma drug exposure, but not at 2.1 times the human dose.

Laboratory Abnormalities

Some patients treated with ZOKINVY developed laboratory abnormalities. These included:

• Electrolyte abnormalities (43%), such as hyperkalemia, hypokalemia, hyponatremia, or hypercalcemia
• Myelosuppression (35%), such as reductions in absolute neutrophil count, white blood cell counts, lymphopenia, hemoglobin, or hematocrit
• Increased liver enzymes, such as aspartate aminotransferase (35%), or alanine aminotransferase (27%)

These laboratory abnormalities often improved while continuing ZOKINVY, but it is not possible to exclude ZOKINVY as a cause of the abnormalities.  Periodically monitor electrolytes, complete blood counts, and liver enzymes, and manage abnormalities accordingly. 

Nephrotoxicity

• Lonafarnib caused nephrotoxicity in rats at plasma drug exposures approximately equal to that achieved with the human dose. Monitor renal function at regular intervals during ZOKINVY therapy.

Retinal Toxicity

• Lonafarnib caused rod-dependent, low-light vision decline in monkeys at plasma drug exposures similar to that achieved with the human dose. Perform ophthalmological evaluation at regular intervals and at the onset of any new visual changes during ZOKINVY therapy.

Impaired Fertility

• Lonafarnib caused impaired fertility in female rats at 1.2 times the human dose based on plasma drug exposure.
• Lonafarnib caused impaired fertility and testicular toxicity in male rats at 1.5 times the human dose based on plasma drug exposure, and toxicity in the male reproductive tract in monkeys at doses lower than the human dose based on plasma drug exposure.

About The Progeria Research Foundation
The Progeria Research Foundation (PRF) was established in 1999 by the family of Sam Berns, a child with Progeria.  Within four years of its founding, the PRF Genetics Consortium, in collaboration with Francis Collins, MD, PhD, discovered the Progeria gene.  PRF has funded and co-coordinated all Zokinvy-associated clinical trials for Progeria and Progeroid Laminopathies, conducted at Boston Children’s Hospital, and supports scientists who conduct Progeria research worldwide.  PRF is the only non-profit organization solely dedicated to finding treatments and the cure for Progeria and its age-related conditions, including heart disease.  PRF’s International Patient Registry includes over 300 children with Progeria in more than 65 countries.  For more information, please visit www.progeriaresearch.org.

About Eiger


Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of first-in-class, well-characterized drugs for serious rare and ultra-rare diseases for patients with high unmet medical needs.

Zokinvy for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient Progeroid Laminopathies is the Company’s first FDA approval.  A Marketing Authorization Application (MAA) has been accepted and is under review by the European Medicines Agency (EMA).  Outside the U.S., Eiger’s established global Managed Access Program, expected to span greater than 40 countries, ensures all children and young adults with Progeria and Progeroid Laminopathies have access to treatment.

Eiger’s lead clinical programs target Hepatitis Delta Virus (HDV) infection, the most serious form of human viral hepatitis.  Eiger is developing two complementary treatments for HDV.  Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial.  Peginterferon lambda is a first-in-class, well-tolerated type III interferon entering Phase 3.

For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

About Rare Pediatric Disease Priority Review Voucher (PRV) Program

Under the FDA’s Rare Pediatric Disease Priority Review Voucher program, the sponsor of a rare pediatric disease drug product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor.  The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the application.  Under the terms of Eiger’s Collaboration and Supply Agreement with The Progeria Research Foundation (PRF), Eiger and PRF would equally share any proceeds from any potential sale of the voucher. 

Note Regarding Forward-Looking Statements
This press release contains “forward-looking” statements that involve substantial risks and uncertainties. All statements other than statements of historical facts, including statements regarding our future financial condition, timing for and outcomes of clinical results, business strategy and plans and objectives for future operations, are forward-looking statements. These forward-looking statements include terminology such as “believe,” “will,” “may,” “estimate,” “continue,” “anticipate,” “contemplate,” “intend,” “target,” “project,” “should,” “plan,” “expect,” “predict,” “could,” “potentially” or the negative of these terms. Forward-looking statements are our current statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our anticipating significant milestones in 2020 and 2021, the timing of our ongoing and planned clinical development, including our ability to support the launch of a new product and ship to specialty pharmacies; our development programs for Zokinvy generally; and the potential approval of Zokinvy in jurisdictions outside of the U.S., including the EU; the risks related to the commercialization of Zokinvy, our ability to manufacture sufficient quantities of Zokinvy, and the commercial launch of Zokinvy in the U.S., the market potential for Zokinvy as a treatment for Progeria and PL; our progression and enrollment of our Phase 3 D-LIVR study in HDV; our ability to maintain supply of our commercial and clinical trial materials; our plans to advance Lambda in HDV in the U.S. and EU; our ability to transition into a commercial stage biopharmaceutical company; our ability to finance the continued advancement of our development pipeline products; and the potential for success of any of our product candidates. These statements concern product candidates that have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA). No representation is made as to their safety or effectiveness for the purposes for which they are being investigated. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Eiger makes, including additional applicable risks and uncertainties described in the “Risk Factors” sections in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 and Eiger’s subsequent filings with the SEC. The forward-looking statements contained in this press release are based on information currently available to Eiger and speak only as of the date on which they are made. Eiger does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.

View original content:http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-announces-fda-approval-of-zokinvy-lonafarnib-the-first-treatment-for-hutchinson-gilford-progeria-syndrome-and-processing-deficient-progeroid-laminopathies-301180247.html

SOURCE Eiger BioPharmaceuticals

VANCOUVER, BC, Nov. 25, 2020 /PRNewswire/ – GoldMining Inc. (the “Company” or “GoldMining”) (TSX: GOLD) (NYSE American: GLDG) is pleased to announce that the Company’s Chairman and founder, Amir Adnani, will present at the H.C. Wainwright Mining Conference on Monday, November 30th, 2020 at 1:30 PM ET.  Investors are invited to register for the GoldMining’s live webcast at: https://bit.ly/3fxAui2

In addition, Mr. Adnani will be speaking at the H.C. Wainwright Mining Panel Discussion, at 12:30 PM ET.  The mining panel will be moderated by Carolin Roth, Freelance Anchor at CNBC International, as part of the H.C. Wainwright’s Virtual “Mining for Some Holiday Cheer” Conference.  Other panelists include: Ross J. Beaty (Pan American Silver Corp.), Robert Quartermain (former CEO of Pretium Resources Inc.), and New York Times bestselling author and fund manager, Marin Katusa. 

Interested investors can register to join the GoldMining’s live webcast and the Mining Panel on Nov 30^th at the H.C. Wainwright’s Virtual Mining Conference at www.hcwevents.com/mining.

About GoldMining Inc.

GoldMining Inc. is a public mineral exploration company focused on the acquisition and development of gold assets in the Americas. Through its disciplined acquisition strategy, GoldMining now controls a diversified portfolio of resource-stage gold and gold-copper projects in Canada, U.S.A., Brazil, Colombia and Peru.

Forward-looking Statements

This document contains certain forward-looking statements that reflect the current views and/or expectations of GoldMining with respect to its business and future events, including expectations and future plans respecting each of GoldMining’s and Gold Royalty’s, business plans and strategies.  Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the business and the markets in which GoldMining and Gold Royalty, operate. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including: the inherent risks involved in the exploration and development of mineral properties, fluctuating metal prices, unanticipated costs and expenses and uncertainties relating to the availability and costs of financing needed in the future. These risks, as well as others, including those set forth in GoldMiningꞌs Annual Information Form for the year ended November 30, 2019, management’s discussion and analysis and other filings with Canadian securities regulators, could cause actual results and events to vary significantly. Accordingly, readers should not place undue reliance on forward-looking statements and information. There can be no assurance that forward-looking information, or the material factors or assumptions used to develop such forward looking information, will prove to be accurate. The Company does not undertake any obligations to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable securities law.

View original content:http://www.prnewswire.com/news-releases/goldmining-to-present-at-the-hc-wainwright-virtual-mining-conference-on-monday-november-30th-301180427.html

SOURCE GoldMining Inc.

CORPUS CHRISTI, TX, Nov. 25, 2020 /PRNewswire/ – Uranium Energy Corp. (NYSE American: UEC) “UEC” or the “Company”) is pleased to announce that the Company’s President and CEO, Amir Adnani, will present at the H.C. Wainwright Mining Conference on Monday, November 30, 2020 at 2:30 PM ET.   

In addition, Mr. Adnani will be speaking at the H.C. Wainwright Mining Panel Discussion, at 12:30 PM ET.  The mining panel will be moderated by Carolin Roth, Freelance Anchor at CNBC International, as part of the H.C. Wainwright’s Virtual “Mining for Some Holiday Cheer” Conference.  Other panelists include: Ross J. Beaty (Pan American Silver Corp.), Robert Quartermain (former CEO of Pretium Resources Inc.), and New York Times bestselling author and fund manager, Marin Katusa. 

Interested investors can register to attend UEC’s live webcast and the Mining Panel on Nov 30^th at the H.C. Wainwright’s Virtual Mining Conference at www.hcwevents.com/mining.

About Uranium Energy Corp

Uranium Energy Corp is a U.S.-based uranium mining and exploration company.  In South Texas, the Company’s hub-and-spoke operations are anchored by the fully-licensed Hobson Processing Facility which is central to the Palangana, Burke Hollow and Goliad ISR projects.  In Wyoming, UEC controls the Reno Creek project, which is the largest permitted, pre-construction ISR uranium project in the U.S.  Additionally, the Company controls a pipeline of uranium projects in Arizona, New Mexico and Paraguay, a uranium/vanadium project in Colorado and a large, high-grade ferro-titanium project in Paraguay.  The Company’s operations are managed by professionals with a recognized profile for excellence in their industry, a profile based on many decades of hands-on experience in the key facets of uranium exploration, development and mining.

Stock Exchange Information:

NYSE American: UEC
WKN: AØJDRR
ISN: US916896103

Safe Harbor Statement

Except for the statements of historical fact contained herein, the information presented in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. Any other statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects” or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans, “estimates” or “intends”, or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and should be viewed as “forward-looking statements”. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements, including statements regarding the anticipated use of proceeds from the offering. Such risks and other factors include, among others, the actual results of exploration activities, variations in the underlying assumptions associated with the estimation or realization of mineral resources, the availability of capital to fund programs and the resulting dilution caused by the raising of capital through the sale of shares, accidents, labor disputes and other risks of the mining industry including, without limitation, those associated with the environment, delays in obtaining governmental approvals, permits or financing or in the completion of development or construction activities, title disputes or claims limitations on insurance coverage. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements contained in this news release and in any document referred to in this news release.

Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the Securities and Exchange Commission. For forward-looking statements in this news release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities.

View original content:http://www.prnewswire.com/news-releases/uranium-energy-corp-to-present-at-the-hc-wainwright-virtual-mining-conference-on-monday-november-30th-301180363.html

SOURCE Uranium Energy Corp

VANCOUVER, BC, Nov. 25, 2020 /PRNewswire/ – Uranium Royalty Corp. (TSX-V: URC) (“URC” or the “Company“) invites investors and shareholders to attend the Company’s presentation at the H.C. Wainwright Mining Conference on Monday, November 30th, 2020 at 4:30 PM ET.  

President and CEO, Scott Melbye, will provide an update on the Company and answer investors questions during his live webcast.   

Mr. Melbye will also be available to participate in one-on-one meetings with investors who are registered to attend the conference via Zoom.   If you are an investor and would like to schedule a meeting with Uranium Royalty Corp, please register for the conference at www.hcwevents.com/mining and request a meeting with URC.

About Uranium Royalty Corp.

Uranium Royalty Corp. is a pure-play uranium royalty company focused on gaining exposure to uranium prices by making strategic investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, as well as through holdings of physical uranium. The Company’s strategy recognizes the inherent cyclicality of valuations based on uranium prices, including the impact of such cyclicality on the availability of capital within the uranium sector and the current historically low uranium pricing environment. The Company intends to execute on its strategy by leveraging the deep industry knowledge and expertise of its management team and the Board to identify and evaluate investment opportunities in the uranium industry. The Company’s management and the Board include individuals with over 130 years of combined experience in the uranium and nuclear energy sectors, including specific expertise in mine finance, project identification and evaluation, mine development and uranium sales and trading.

Forward Looking Statements

Certain statements in this news release may constitute “forward-looking statements”, including statements on the anticipated date the Company’s securities will commence trading on the TSX-V. Forward-looking statements are statements that address or discuss activities, events or developments that the Company expects or anticipates may occur in the future. When used in this news release, words such as “estimates”, “expects”, “plans”, “anticipates”, “will”, “believes”, “intends” “should”, “could”, “may” and other similar terminology are intended to identify such forward-looking statements. Forward-looking statements reflect the current expectations and beliefs of the Company’s management. Because forward-looking statements involve known and unknown risks, uncertainties and other factors, actual results, performance or achievements of the Company and its industry may be materially different from those implied by such forward-looking statements. Forward-looking statements involve significant uncertainties, should not be read as a guarantee of future performance or results, and will not necessarily be an accurate indication of whether or not such results will be achieved. A number of factors could cause actual results to differ materially from the results discussed in the forward-looking statements, including, without limitation, the ability of the Company to identify and execute future acquisitions on acceptable terms or at all, risks inherent to royalty companies, fluctuations in the market price of publicly listed shares held by the Company, currency fluctuations, uranium price volatility, title and permitting matters, risks related to the operators of the projects underlying the Company’s interests, political or economic developments in the countries in which the Company holds its royalty and other interests, litigation, general economic conditions and those other risks described in the Company’s final long form prospectus dated November 22, 2019 and other disclosure documents, available on SEDAR at www.sedar.com. These risks, as well as others, could cause actual results and events to vary significantly. Accordingly, readers should exercise caution in relying upon forward-looking statements and the Company undertakes no obligation to publicly revise them to reflect subsequent events or circumstances, except as required by law.   Neither the TSX-V nor its Regulation Services Provider (as that term is defined in policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.

View original content:http://www.prnewswire.com/news-releases/uranium-royalty-corp-to-present-at-the-hc-wainwright-virtual-mining-conference-on-monday-november-30th-at-430-pm-et-301180438.html

SOURCE Uranium Royalty Corp.

LOS ANGELES, Nov. 25, 2020 /PRNewswire/ — Black Market, a new virtual venue, is partnering with Toyota Motor North America (TMNA) and actor, model and entertainer Terrence J, to launch a virtual fashion event to support up-and-coming Black designers in the fashion industry, who are often not provided the same opportunities as their peers. Select Black designers and their brands will be showcased on the Black Market platform, which will launch November 25 and feature runway shows and exclusive content through November 27.

“The influence of the Black community and Black designers on fashion is undeniable, but that’s often not reflected in the opportunities provided to us,” said Terrence J. “I’m excited to partner with Black Market, to give Black designers a much-needed platform to showcase Black Excellence, and help level the playing field in fashion.”

Despite the noted influence of the Black community on global fashion trends, Black designers have historically not been provided with the same prominent opportunities as their peers to advance on the business side of the fashion industry. To help bridge this gap, Black Market is partnering with designers, entertainers, and fashion brands for a unique and immersive fashion experience designed exclusively for Black designers to showcase their work and for consumers to have easy access for purchase.

In partnership with TMNA, selected designers participating in the Black Market virtual fashion event will select one item from their collection, to be featured exclusively in the Toyota Closet. The Toyota Closet will house limited edition looks from the Black designers, all of which can only be accessed through the virtual closet. Consumers can register for free access to the Toyota Closet here.

“Toyota is proud to partner with Black Market in their work to celebrate and honor emerging Black designers,” said Kelsey Charles, engagement marketing planner, TMNA. “We are committed to supporting diverse platforms that not only champion creativity but promote inclusivity.”

The virtual fashion event will kick off on November 25 and culminates on Black Friday, November 27. It will include virtual runway shows, interviews with the featured designers, exclusive fashion giveaways, and appearances from Terrence J, to support the featured brands on Black Market, including: New Levels New Devils, Lila Nicole Swimwear, Shift Style House, Legacy History Pride, House of Bartholomew, Tote N Carry, Gabriel Salcedo, and Miguel Wilson Collection. For more information on the featured brands and designers, visit Black Market Showroom.

“While Fashion Week has annually been a showcase for top fashion brands and designers, for many Black designers it was never their platform,” said Derrick Brown, Founder, Black Market. “With Black Market, and our partnership with Toyota and Terrence J, we’re happy to create a platform for Black designers to showcase their work, and also provide a marketplace for their designs that makes it accessible for consumers.”

About Black Market
While the prominent role Black people play setting global fashion trends is undeniable Black designers are being denied their rightful place in the business side of the cultural trends they are constantly creating. To combat this, Black Market is partnering with designers, entertainers and brands to deliver unique and immersive experiences designed exclusively for Black designers. Black Market is digital/mobile destination created to give Black designers a tool to showcase, promote and sell their products and consumers a destination where they can discover and purchase the top Black owned brands.

About Toyota

Toyota (NYSE:TM) has been a part of the cultural fabric in the U.S. for more than 60 years, and is committed to advancing sustainable, next-generation mobility through our Toyota and Lexus brands, plus our nearly 1,500 dealerships. 

Toyota has created a tremendous value chain and directly employs more than 36,000 in the U.S. The company has contributed world-class design, engineering, and assembly of more than 30 million cars and trucks at our 9 manufacturing plants, 10 including our joint venture in Alabama that begins production in 2021.

To help inspire the next generation for a career in STEM-based fields, including mobility, Toyota launched its virtual education hub at

www.TourToyota.com

 with an immersive experience and chance to visit many of our U.S. manufacturing facilities. The hub also includes a series of free STEM-based lessons and curriculum through Toyota USA Foundation partners, virtual field trips and more. For more information about Toyota, visit

www.toyotanewsroom.com

.

CONTACT


Derrick Brown

Black Market

[email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/black-market-launches-virtual-platform-to-showcase-black-designers-301180398.html

SOURCE Black Market

NEW YORK, Nov. 25, 2020 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for YJ, HPQ, WEI, COCP, and MESA.

To see how InvestorsObserver’s proprietary scoring system rates these stocks, view the InvestorsObserver’s PriceWatch Alert by selecting the corresponding link.

• YJ: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=YJ&prnumber=112520201
• HPQ: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=HPQ&prnumber=112520201
• WEI: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=WEI&prnumber=112520201
• COCP: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=COCP&prnumber=112520201
• MESA: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=MESA&prnumber=112520201

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver’s PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock’s overall suitability for investment.

View original content to download multimedia:http://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-yunji-hp-weidai-cocrystal-pharma-or-mesa-air-301180569.html

SOURCE InvestorsObserver